Christian Laurent

Summary

Country: France

Publications

  1. ncbi The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study
    Christian Laurent
    Institut de Recherche pour le Développement UR 36 and University of Montpellier, France
    AIDS 16:1363-70. 2002
  2. pmc HIV and hepatitis C virus coinfection, Cameroon
    Christian Laurent
    Emerg Infect Dis 13:514-6. 2007
  3. ncbi Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine
    Christian Laurent
    IRD, UMR 145 IRD University of Montpellier 1, Montpellier, France
    AIDS 21:768-71. 2007
  4. ncbi Antiretroviral therapy in public and private routine health care clinics in Cameroon: lessons from the Douala antiretroviral (DARVIR) initiative
    Christian Laurent
    Institut de Recherche pour le Developpement, Department of International Health, University of Montpellier UMR 145, Montpellier, France
    Clin Infect Dis 41:108-11. 2005
  5. ncbi [Cluster sampling: consequences of data analysis on drawing conclusions]
    C Laurent
    Institut de Recherche pour le Développement et Département de Santé Internationale, Université de Montpellier UMR 145, 911, Avenue Agropolis, BP 64501, 34394 Montpellier Cedex 5
    Rev Epidemiol Sante Publique 53:43-50. 2005
  6. ncbi Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults
    Christian Laurent
    Institut de Recherche pour le Développement and Department of International Health, University of Montpellier UMR 145, France
    J Acquir Immune Defic Syndr 38:14-7. 2005
  7. pmc Commercial logging and HIV epidemic, rural Equatorial Africa
    Christian Laurent
    Institut de Recherche pour le Développement UMR 145, Montpellier, France
    Emerg Infect Dis 10:1953-6. 2004
  8. ncbi No difference in clinical progression between patients infected with the predominant human immunodeficiency virus type 1 circulating recombinant form (CRF) 02_AG strain and patients not infected with CRF02_AG, in Western and West-Central Africa: a four-ye
    Christian Laurent
    Institut de Recherche pour le Développement IRD UR 36 and Department of International Health, University of Montpellier, France
    J Infect Dis 186:486-92. 2002
  9. doi Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon
    Christian Laurent
    Institut de Recherche pour le Developpement, UMR 145 IRD University of Montpellier 1, Montpellier, France
    AIDS Res Hum Retroviruses 24:393-9. 2008
  10. pmc Antiretroviral drug resistance and routine therapy, Cameroon
    Christian Laurent
    Institut de Recherche pour le Développement UMR 145, Montpellier, France
    Emerg Infect Dis 12:1001-4. 2006

Collaborators

Detail Information

Publications39

  1. ncbi The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study
    Christian Laurent
    Institut de Recherche pour le Développement UR 36 and University of Montpellier, France
    AIDS 16:1363-70. 2002
    ..To study the feasibility, effectiveness, adherence, toxicity and viral resistance in an African government HAART initiative...
  2. pmc HIV and hepatitis C virus coinfection, Cameroon
    Christian Laurent
    Emerg Infect Dis 13:514-6. 2007
  3. ncbi Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine
    Christian Laurent
    IRD, UMR 145 IRD University of Montpellier 1, Montpellier, France
    AIDS 21:768-71. 2007
    ..Virological effectiveness appeared to wane somewhat during the second year of treatment, however, and plasma nevirapine concentrations were relatively high...
  4. ncbi Antiretroviral therapy in public and private routine health care clinics in Cameroon: lessons from the Douala antiretroviral (DARVIR) initiative
    Christian Laurent
    Institut de Recherche pour le Developpement, Department of International Health, University of Montpellier UMR 145, Montpellier, France
    Clin Infect Dis 41:108-11. 2005
    ..Virological and immunologic effectiveness of therapy was as expected in patients for whom results were available...
  5. ncbi [Cluster sampling: consequences of data analysis on drawing conclusions]
    C Laurent
    Institut de Recherche pour le Développement et Département de Santé Internationale, Université de Montpellier UMR 145, 911, Avenue Agropolis, BP 64501, 34394 Montpellier Cedex 5
    Rev Epidemiol Sante Publique 53:43-50. 2005
    ..This note illustrates that the precision of parameters such as mean, prevalence and odds ratio can be biased when the data analysis ignores the sampling design, yielding to possibly erroneous conclusions...
  6. ncbi Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults
    Christian Laurent
    Institut de Recherche pour le Développement and Department of International Health, University of Montpellier UMR 145, France
    J Acquir Immune Defic Syndr 38:14-7. 2005
    ....
  7. pmc Commercial logging and HIV epidemic, rural Equatorial Africa
    Christian Laurent
    Institut de Recherche pour le Développement UMR 145, Montpellier, France
    Emerg Infect Dis 10:1953-6. 2004
    ..The vulnerability of these young women could be related to commercial logging and the social and economic networks it induces. The environmental changes related to this industry in Equatorial Africa may facilitate HIV dissemination...
  8. ncbi No difference in clinical progression between patients infected with the predominant human immunodeficiency virus type 1 circulating recombinant form (CRF) 02_AG strain and patients not infected with CRF02_AG, in Western and West-Central Africa: a four-ye
    Christian Laurent
    Institut de Recherche pour le Développement IRD UR 36 and Department of International Health, University of Montpellier, France
    J Infect Dis 186:486-92. 2002
    ..01; 95% CI, -0.82 to 0.81; P=.9). This study suggests that the predominance of HIV-1 CRF02_AG strain in western and west-central Africa should have no major clinical consequences...
  9. doi Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon
    Christian Laurent
    Institut de Recherche pour le Developpement, UMR 145 IRD University of Montpellier 1, Montpellier, France
    AIDS Res Hum Retroviruses 24:393-9. 2008
    ..In view of stavudine toxicity, these results support recommendations calling for a gradual switch from stavudine- to zidovudine-based regimens...
  10. pmc Antiretroviral drug resistance and routine therapy, Cameroon
    Christian Laurent
    Institut de Recherche pour le Développement UMR 145, Montpellier, France
    Emerg Infect Dis 12:1001-4. 2006
    ..4% had drug resistance after a median of 10 months. Of these, 12.5% had resistance to nucleoside reverse transcriptase inhibitors (NRTIs), 10.2% to non-NRTIs, and 2.3% to protease inhibitors...
  11. ncbi Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon
    Anke Bourgeois
    Institut de Recherche pour le Développement and Department of International Health, University of Montpellier UMR 145, Montpellier, France
    Antivir Ther 10:335-41. 2005
    ..To assess the effectiveness of generic anti-retroviral drugs in terms of survival and virological and immunological responses, as well as their tolerability and the emergence of viral resistance...
  12. ncbi Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial
    Christian Laurent
    Institut de Recherche pour le Développement and Department of International Health, University of Montpellier UMR 145, Montpellier, France
    Lancet 364:29-34. 2004
    ..We aimed to assess these issues for one of the most frequently prescribed treatments in Africa, a generic fixed-dose combination of nevirapine, stavudine, and lamivudine...
  13. ncbi Biological and genetic characteristics of HIV infections in Cameroon reveals dual group M and O infections and a correlation between SI-inducing phenotype of the predominant CRF02_AG variant and disease stage
    Laurence Vergne
    Laboratoire Retrovirus, UR36, Institut de Recherche pour le Developpement, 911 Av Agropolis, BP64501, 34394 Montpellier Cedex 5, France
    Virology 310:254-66. 2003
    ..The two predominant HIV-1 variants in Africa, CRF02_AG and subtype C, thus have different biological characteristics...
  14. ncbi Low rate of genotypic HIV-1 drug-resistant strains in the Senegalese government initiative of access to antiretroviral therapy
    Laurence Vergne
    Institut de recherche pour le developpement IRD, UR 36, University of Montpellier, France
    AIDS 17:S31-8. 2003
    ..To monitor the prevalence of antiretroviral (ARV)-resistant HIV-1 viruses, and the genotypic mutations in patients enrolled in the Senegalese initiative for access to antiretroviral treatment (ART)...
  15. doi Prediction of HIV drug resistance based on virologic, immunologic, clinical, and/or adherence criteria in the Stratall ANRS 12110/ESTHER trial in Cameroon
    Charlotte Boullé
    Institut de recherche pour le developpement IRD, University Montpellier 1, UMI 233 TransVIHMI, Montpellier, France
    Clin Infect Dis 57:604-7. 2013
    ..Switching to second-line antiretroviral therapy after 2 consecutive viral loads ≥5000 copies/mL, as recommended by the World Health Organization, appeared to be the most appropriate strategy. ..
  16. pmc Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon
    Jules B Tchatchueng Mbougua
    Institut de Recherche pour le Developpement, University Montpellier 1, UMR 145, Montpellier, France
    BMC Public Health 10:105. 2010
    ....
  17. doi Task shifting HIV care in rural district hospitals in Cameroon: evidence of comparable antiretroviral treatment-related outcomes between nurses and physicians in the Stratall ANRS/ESTHER trial
    Charlotte Boullé
    UMI 233, Institut de recherche pour le developpement IRD, University Montpellier 1, Montpellier, France
    J Acquir Immune Defic Syndr 62:569-76. 2013
    ..We assessed the effectiveness of task shifting from physicians to nurses in rural district hospitals in Cameroon...
  18. ncbi Prevalence of HIV and other sexually transmitted infections, and risk behaviours in unregistered sex workers in Dakar, Senegal
    Christian Laurent
    Institut de Recherche pour le Développement IRD UR 36 and Department of International Health, University of Montpellier, France
    AIDS 17:1811-6. 2003
    ....
  19. ncbi HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon
    Laurence Vergne
    UMR145, Institut de Recherche pour le Développement IRD and University of Montpellier, Montpellier, France
    Antivir Ther 11:575-9. 2006
    ..Population surveillance for ARV drug resistance is required and should be included in all implementation programmes...
  20. ncbi Safety of stavudine in the treatment of HIV infection with a special focus on resource-limited settings
    Alain Makinson
    University Hospital, Department of Infectious and Tropical Diseases, Montpellier, France
    Expert Opin Drug Saf 7:283-93. 2008
    ..Yet it remains a cornerstone of treatment in resource-limited settings, due to lack of alternatives and its availability in generic fixed-dose combinations...
  21. doi Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon
    Amandine Cournil
    Institut de Recherche pour le Developpement, University Montpellier 1, Montpellier, France
    Antivir Ther 15:1039-43. 2010
    ..This study assessed the effect of stavudine (d4T) 30 mg dosage on lipoatrophy in HIV-infected patients on antiretroviral treatment...
  22. doi Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal
    Christian Laurent
    Institut de Recherche pour le Developpement, University Montpellier 1, UMR 145, Montpellier, France
    Trop Med Int Health 16:217-22. 2011
    ....
  23. doi Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial
    Christian Laurent
    Institut de recherche pour le developpement IRD, University Montpellier 1, UMI 233, Montpellier, France
    Lancet Infect Dis 11:825-33. 2011
    ..We aimed to assess the effectiveness and safety of clinical monitoring alone (CLIN) in terms of non-inferiority to laboratory and clinical monitoring (LAB)...
  24. ncbi Distribution of HIV-1 variants in the Democratic Republic of Congo suggests increase of subtype C in Kinshasa between 1997 and 2002
    Nicole Vidal
    UR36, Institut de Recherche pour e Developement IRD, Montpellier, France
    J Acquir Immune Defic Syndr 40:456-62. 2005
    ..These changes could have implications regarding the spread of HIV infection in the DRC as well on vaccine and/or treatment strategies...
  25. pmc Evaluation of different RNA extraction methods and storage conditions of dried plasma or blood spots for human immunodeficiency virus type 1 RNA quantification and PCR amplification for drug resistance testing
    Marjorie Monleau
    UMR 145, Institut de Recherche pour le Developpement, and University of Montpellier 1, Montpellier, France
    J Clin Microbiol 47:1107-18. 2009
    ..DBS could be used as an alternative for DPS depending on HIV RNA cutoffs for virological failure. VL measurements remain stable over a longer period than do PCR amplification results...
  26. pmc Virological outcome and patterns of HIV-1 drug resistance in patients with 36 months' antiretroviral therapy experience in Cameroon
    Avelin F Aghokeng
    Virology Laboratory CREMER IMPM IRD, Yaounde, Cameroon
    J Int AIDS Soc 16:18004. 2013
    ..We assessed the virological outcome and drug resistance mutations in patients with 36 months' ART experience, and monitored according to the WHO public health approach in Cameroon...
  27. ncbi Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study
    Jean Francois Etard
    UMR 145 HIV AIDS and Associated Diseases, Research Institute for Development IRD University of Montpellier, 911 Avenue Agropolis, 34394 Montpellier Cedex 1, France
    AIDS 20:1181-9. 2006
    ..To evaluate survival and investigate causes of death among HIV-1 infected adults receiving HAART in Senegal...
  28. ncbi Widely varying SIV prevalence rates in naturally infected primate species from Cameroon
    Avelin F Aghokeng
    Laboratoire Retrovirus, UMR145, IRD, Institute for Research and Development, Montpellier, France
    Virology 345:174-89. 2006
    ..The newly developed assays should now permit to define with greater accuracy existing SIV reservoirs and associated human zoonotic risk...
  29. doi Commentary: Early antiretroviral therapy for HIV infection in sub-Saharan Africa, a challenging new step
    Christian Laurent
    Institut de Recherche pour le Développement UMR 145, 911 Avenue Agropolis, BP 64501, 34394 Montpellier, Cedex 5, France
    J Public Health Policy 31:401-6. 2010
    ..Leaders at both levels must take their responsibilities and mobilize the necessary resources, for example, doubling those for the Global Fund to Fight AIDS, Tuberculosis and Malaria from $10 billion to $20 billion USD for 2011-2013...
  30. doi Commentary: HIV testing in low- and middle-income countries: an urgent need for scaling up
    Christian Laurent
    Institut de Recherche pour le Développement UMI 233, 911 Avenue Agropolis, BP 64501, 34394 Montpellier Cedex 5, France
    J Public Health Policy 34:17-21. 2013
    ..The successful Rwandan experience of scaling up early infant HIV diagnosis brings hope for many countries...
  31. pmc Susceptibility to transmitting HIV in patients initiating antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER Trial)
    Gilbert Ndziessi
    INSERM, UMR912, SESSTIM, Marseille, France
    PLoS ONE 8:e62611. 2013
    ..Using cohort data nested in a randomized trial conducted in Cameroon, this study aimed to investigate time trends and predictors of the susceptibility to transmitting HIV during the first 24 months of treatment...
  32. ncbi Seroepidemiological survey of hepatitis C virus among commercial sex workers and pregnant women in Kinshasa, Democratic Republic of Congo
    C Laurent
    , , Montpellier, France
    Int J Epidemiol 30:872-7. 2001
    ..8%). CONCLUSION: The role of sexual transmission in the spread of HCV seems to be limited. Parenteral transmission (including blood transfusion and injections), possibly related to the treatment of STI, probably plays a major role...
  33. doi Changes in the renal function after tenofovir-containing antiretroviral therapy initiation in a Senegalese cohort (ANRS 1215)
    Pierre De Beaudrap
    Institut de recherche pour le developpement IRD, Université Montpellier1, Montpellier, France
    AIDS Res Hum Retroviruses 26:1221-7. 2010
    ..A significant though moderate decline in the renal function was observed in one-third of the patients receiving TDF compared to patients not receiving TDF. Moreover, this impairment was persistent after the first year of treatment...
  34. doi High rates of active hepatitis B and C co-infections in HIV-1 infected Cameroonian adults initiating antiretroviral therapy
    C Laurent
    Institut de Recherche pour le Developpement, University Montpellier 1, Montpellier, France
    HIV Med 11:85-9. 2010
    ..To investigate the presence of hepatitis B virus (HBV) DNA and hepatitis C virus (HCV) RNA in HIV-infected patients initiating antiretroviral therapy in Cameroon...
  35. ncbi Cohort Profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts
    Francois Dabis
    INSERM U 593, ISPED, Universite Victor Segalen, Bordeaux Cedex, France
    Int J Epidemiol 34:979-86. 2005
  36. doi Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration
    Paula Braitstein
    Department of Medicine, Indiana University, Indianapolis, Indiana, USA
    J Womens Health (Larchmt) 17:47-55. 2008
    ....
  37. ncbi Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries
    Paula Braitstein
    Lancet 367:817-24. 2006
    ..We compared baseline characteristics and outcomes during the first year of HAART between HIV-1-infected patients in low-income and high-income settings...
  38. pmc Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries
    Martin W G Brinkhof
    Institute of Social and Preventive Medicine, Bern, Switzerland
    Bull World Health Organ 86:559-67. 2008
    ..To analyse the early loss of patients to antiretroviral therapy (ART) programmes in resource-limited settings...
  39. doi Adherence to antiretroviral therapy assessed by drug level monitoring and self-report in cameroon
    Charles Kouanfack
    Central Hospital, Yaounde, Cameroon
    J Acquir Immune Defic Syndr 48:216-9. 2008
    ..To compare adherence to antiretroviral therapy using drug level monitoring and self-report and to explore the relation between these 2 methods and viral load measurements...